LeMaitre Vascular (LMAT) Q3 2026 Earnings Call Transcript

LeMaitre Vascular reported Q3 2026 net sales of $68.0 million, up 11% reported and 12% organically, with adjusted diluted EPS of $0.65, up 5% year over year. Management reiterated 11% full-year organic revenue growth guidance and forecast adjusted EPS of $2.77–$2.82, up 18%; cash and marketable securities were $390 million. Growth was offset by integration complexity for the $19.2 million B. Braun acquisition, a likely 18–24-month sales transition, possible back orders, and cardiac allograft processing constraints despite 65% growth.

Analysis

The key underwriting question is conversion, not demand: LMAT has evidence of pricing power and procedure growth, but expanding sales coverage and acquired-product revenue will only create durable operating leverage if the company can move products through quality release and avoid customer attrition during the B. Braun contract transition. The cardiac allograft constraint is a near-term growth ceiling rather than evidence of weak demand; however, adding headcount alone may not clear a quality-control bottleneck. Watch whether inventory growth turns into released product and shipments, rather than accumulating further.

The B. Braun assets offer a channel-expansion option, but the acquired portfolio was roughly flat in the cited periods and legacy bundled contracts create a real risk of lost accounts before LMAT can sell directly. This also makes early reported revenue a poor read-through on the acquisition’s ultimate economics. In Europe, LMAT’s channel build-out could improve access over time, while competing with established suppliers such as Terumo Aortic; the potential benefit should be discounted until customer transfers and direct-market execution are visible.

Near term, the result supports a constructive fundamental view, but the quality of growth is mixed: price contributed more than units, while operating expense growth exceeded organic sales growth. Over 1–3 months, focus on Q4 execution and evidence that allograft release capacity is improving. Over 6–18 months, Burlington consolidation, B. Braun account retention, and the likely 2027 FDA reinspection are the larger swing factors. The contrarian risk is extrapolating demand-led growth without enough discount for operational friction and investment spending.

Key Decisions for Investors

• Maintain a watch-list long bias in LMAT, but do not chase an earnings-day gap without valuation and price-action context. Reassess after the next quarterly report for evidence that quality-release throughput is converting demand into shipments and that expense growth is moderating relative to sales.
• Treat the B. Braun acquisition as an option, not near-term earnings support. Track transferred accounts, customer losses from bundled contracts, back orders, and the pace of revenue recognized by LMAT; a sustained decline in acquired-product sales or prolonged supply disruption would weaken the thesis.
• Falsifiers: further deterioration in operating margin alongside continued commercial spending; allograft inventory rising without improving quality release or sales; or adverse FDA findings at the New Jersey facility. Conversely, improving allograft throughput and successful account transfers would strengthen the medium-term case.